Synaptogenix, Inc. Share Price Other OTC
Equities
SNPX
US87167T1025
Biotechnology & Medical Research
Sales 2022 | - | Sales 2023 | - | Capitalization | 5.54M 463M |
---|---|---|---|---|---|
Net income 2022 | -5M -417M | Net income 2023 | -6M -501M | EV / Sales 2022 | - |
Net cash position 2022 | 37.48M 3.13B | Net cash position 2023 | 30.1M 2.51B | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.42
x | P/E ratio 2023 |
-0.23
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 97.57% |
Managers | Title | Age | Since |
---|---|---|---|
Alan Tuchman
CEO | Chief Executive Officer | 77 | 01/18/01 |
Daniel Alkon
PSD | President | 81 | 07/20/07 |
Robert Weinstein
DFI | Director of Finance/CFO | 64 | 01/13/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Tuchman
CEO | Chief Executive Officer | 77 | 01/18/01 |
Bruce Bernstein
BRD | Director/Board Member | 60 | 14/16/14 |
Joshua Silverman
CHM | Chairman | 53 | 04/16/04 |
1st Jan change | Capi. | |
---|---|---|
+22.81% | 46.81B | |
+46.56% | 41.29B | |
-1.88% | 41.37B | |
-6.20% | 28.87B | |
+11.33% | 26.06B | |
-21.00% | 19.13B | |
-1.43% | 11.96B | |
+30.73% | 12.39B | |
-0.48% | 12.08B |